MetALD: New Perspectives on an Old Overlooked Disease

Liver International, Journal Year: 2025, Volume and Issue: 45(5)

Published: April 3, 2025

ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated (ALD) are the major contributors to burden globally. The rise in these conditions is linked obesity, type 2 diabetes, metabolic syndrome increased alcohol consumption. MASLD ALD share risk factors, pathophysiology histological features but differ their thresholds for use, definition does not require presence of dysfunction. A recent multi‐society consensus overhauled nomenclature steatosis introduced term MetALD describe patients with dysfunction who drink more than those less ALD. This new terminology aims enhance understanding management poses challenges, such as need accurately measure consumption research clinical practice settings. Recent studies show that has significant implications patient management, it associated mortality risks severe outcomes compared alone. face progression, cancer cardiovascular disease. diagnosis involves adequate quantification use through standardised questionnaires and/or biomarkers well proper assessment stage progression using non‐invasive tools including serologic markers, imaging, elastography techniques genetic testing. Effective requires addressing both alcohol‐related factors improve outcomes. review intends provide a comprehensive overview MetALD, covering pathogenesis, potential diagnostic approaches, strategies emerging therapies.

Language: Английский

---

Possible link between steatotic liver diseases, severe COVID-19 and cognitive impairment in post-COVID-19 syndrome

Infection, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

Abstract Purpose Steatotic liver diseases (SLD) have become more prevalent over the last decade and are associated not only with cardiometabolic but also psychological symptoms (depression, fatigue). These common in post-COVID syndrome (PCS). Therefore, aim of study was to analyze burden SLD PCS patients. Methods We systematically screened all patients from our outpatient clinic using transient elastography, structured questionnaires for neurocognitive evaluation blood sample analysis. Controls without known were recruited assessed same approach. Results 560 103 healthy controls included. The overall prevalence high both cohorts (57 vs. 53%). frequently male (41 24%), older (52 44 years) had (87.0 46.4%). Cognitive impairment related than no-SLD group (OR: 1.68, CI: 1.14–2.46, p = 0.008). presence severe COVID-19 hospitalization 2.91, 1.85–4.56, < 0.001). Within 1 year follow-up, 152 289 described a resolution irrespective or absence (log-rank 0.96). Conclusions is cognitive dysfunction PCS. Longitudinal studies needed assess role hepatic steatosis, development post-acute infection regulation (e.g., SARS-CoV-2) differentiate between SLD-associated

Language: Английский

---

Reply to “Is liver fibrosis more advanced in MetALD than in MASLD?”

Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

---

Impact of MASLD on Portal Vein Thrombosis Following Hepatectomy for Liver Cancer

Cancers, Journal Year: 2024, Volume and Issue: 16(22), P. 3844 - 3844

Published: Nov. 15, 2024

: Due to the increasing global prevalence of non-alcoholic fatty liver disease (NAFLD), which is closely linked metabolic disorders, there has been a rise in number patients with NAFLD undergoing hepatectomy. The as well NAFLD, increase venous thrombotic risk. was recently updated new concept hepatic steatosis: dysfunction-associated steatotic (MASLD). We aimed investigate impact MASLD on post-hepatectomy portal vein thrombosis (PH-PVT).

Language: Английский

---